BDSI
is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions... Read moreBDSI
is a North Carolina-based pharmaceutical company that develops and commercializes novel therapies for the treatment of debilitating chronic conditions... Read more
News
Mar 22, 2022
Life Care News
BDSI: Collegium Completes the Acquisition of BDSI
Feb 24, 2022
FirstWord Pharma
BDSI: BioDelivery Sciences International Announces ELYXYB is Now Available in the U.S. for the Acute Treatment of Migraine
Feb 19, 2022
Global Legal Chronicle
BDSI: Collegium Pharmaceutical's Acquisition of BioDelivery Sciences International
Feb 15, 2022
MarketScreener
BDSI: BioDelivery Sciences International : Material Definitive Agreement - Form 8-K/A
Feb 15, 2022
Benzinga
BDSI: BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery Sciences International, Inc. (Nasdaq - BDSI), Zurn Water Solutions Corporation (NYSE - ZWS), Edoc Acquisition Corp. (Nasdaq - ADOC)
Feb 15, 2022
MarketScreener
BDSI: SHAREHOLDER ALERT: WeissLaw LLP Investigates BioDelivery Sciences International, Inc.
Feb 15, 2022
Medthority
BDSI: Collegium Pharma acquires Biodelivery Sciences International Inc., and with it Belbuca , Symproic and Elyxyb.
Feb 15, 2022
Pharamceutical Technology
BDSI: Collegium Pharmaceutical to purchase BioDelivery Sciences for $604m
Feb 15, 2022
Seeking Alpha
BDSI: BioDelivery Sciences Buyout Is Good, Not Great
Feb 15, 2022
MedCity News
BDSI: Collegium diversifies with $604M BDSI buyout, adding pain & migraine meds
BDSI Competitors
1
2
3
4
5
6
7
8
9
10